【摘要】 目的对低剂量地西他滨皮下注射治疗骨髓增生异常综合征的国内外研究进展进行综述。方法在Pubmed、中国知网、万方等数据资源库检索近年国内外相关文献,阐明地西他滨治疗骨髓增生异常综合征的作用机制,并对低剂量皮下注射的疗效及安全性进行总结与评价。结果低剂量地西他滨皮下注射能靶向抑制DNA甲基转移酶活性,在发挥抗肿瘤效应同时减轻细胞毒性。与常规静脉给药方案相比,其疗效肯定、作用安全、给药方便、耐受性良好,同时可降低用药剂量、减轻经济负担,提高患者生存质量。结论低剂量地西他滨皮下注射对不能耐受高剂量化疗与无法接受造血干细胞移植的患者而言或可成为一种较优的治疗选择,具有广阔的应用前景,其联合用药方案值得深入探索研究。更多还原

【Abstract】 Objective To review the domestic and international research progress of low-dose decitabine subcutaneous injection for the treatment of myelodysplastic syndromes. Methods Retrieving the relevant references both at home and abroad in recent years in databases such as Pubmed, CNKI, Wanfang, etc, elucidating the mechanism of decitabine in the treatment of myelodysplastic syndromes, furthermore summarizing and evaluating the efficacy and safety of low-dose subcutaneous injection.Results Low-dose decitabine subcutaneous injection exerts anti-tumor effects while reducing cytotoxicity by targeted DNA methyltransferase inhibition. Compared with the conventional intravenous administration regimen, it has a positive effect, safe action, convenient administration, and good tolerability. At the same time, it can reduce the dosage and the economic burden, and improve the quality of life of patients.Conclusion Low-dose decitabine subcutaneous injection may be a better treatment option for patients who cannot tolerate high-dose chemotherapy and cannot receive hematopoietic stem cell transplantation. It has broad application prospects, and its combination regimen is worthy of in-depth exploration and research.更多还原